Invention Grant
- Patent Title: Selective inhibitor of exon 20 insertion mutant EGFR
-
Application No.: US16345792Application Date: 2017-10-31
-
Publication No.: US11857513B2Publication Date: 2024-01-02
- Inventor: Kazutaka Miyadera , Yoshimi Aoyagi , Shinichi Hasako
- Applicant: Taiho Pharmaceutical Co., Ltd.
- Applicant Address: JP Tokyo
- Assignee: Taiho Pharmaceutical Co., Ltd.
- Current Assignee: Taiho Pharmaceutical Co., Ltd.
- Current Assignee Address: JP Tokyo
- Agency: Oblon, McClelland, Maier & Neustadt, L.L.P.
- Priority: JP 16213072 2016.10.31
- International Application: PCT/JP2017/037186 2017.10.31
- International Announcement: WO2018/079310A 2018.05.03
- Date entered country: 2019-04-29
- Main IPC: A61K31/519
- IPC: A61K31/519 ; A61P35/00
Abstract:
An antitumor agent comprising a compound selected from the group consisting of Compounds A to D described in the specification, or a salt thereof, for treating a malignant tumor patient expressing EGFR having exon 20 insertion mutation.
Public/Granted literature
- US20190262345A1 SELECTIVE INHIBITOR OF EXON 20 INSERTION MUTANT EGFR Public/Granted day:2019-08-29
Information query
IPC分类:
